In hematologic malignancies, germline or somatic PTPN11 mutations drive leukemogenesis in juvenile myelomonocytic leukemia (JMML) and acute myeloid leukemia (AML), where SHP2 activity predicts disease severity and relapse risk [90]. The gene discussed is PTPN11; the disease is acute myeloid leukemia.